Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHari Chandrika MaddineniSPSridevi R. Pitta

Discussion

Loading...

Member takes

Overview

Real-world analysis reveals fixed-duration venetoclax-obinutuzumab improves patient-centered outcomes in CLL, indicating its clinical advantage over continuous regimens.

Key Points

  • Venetoclax-based fixed-duration treatment shows better real-world effectiveness and patient-centered outcomes in chronic lymphocytic leukemia.
  • At 12 months, time to next treatment favored venetoclax-obinutuzumab at 87.1% versus 75.3% for continuous therapies.
  • Assessment included observational studies comparing first-line treatments in adults with chronic lymphocytic leukemia.
  • Venetoclax therapy may support evolving treatment standards, highlighting the benefits of time-limited regimens.

Cite This Study

Maddineni et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6bdhttps://doi.org/10.1182/blood-2025-7437
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials2025
  2. 2Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma2025
  3. 3Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  4. 4Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  5. 5Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia2025